Typical and atypical antipsychotic drugs have been reported to affect basal dopaminergic activity differentially in nigrostriatal and limbic structures after acute and chronic administration in animals. In addition, glutamate has been implicated in the pathophysiology of schizophrenia. The purpose of this study was to examine basal and locally stimulated glutamate and dopamine efflux in the caudate, nucleus accumbens, and medial prefrontal cortex using in viva microdialysis after chronic clozapine and haloperidol treatment. Basal extracellular concentrations of dopamine in the caudate and nucleus accumbens
were not different between the drug treatment groups; however, dopamine concentrations were higher in the medial prefrontal cortex after chronic clozapine treatment.
Depolarization Chronic administration of antipsychotic drugs is a mainstay therapy for the treatment of psychoses. Although the acute effects of these agents with regard to their dopamine antagonist properties have been well characterized (Creese et al., 1976; Seeman et al., 1976; Meltzer et al., 1989; Stockmeier et al., 1993) results regarding their brain region-selective effects on mesostriatal and mesolimbic dopamine systems following chronic treatment are inconsistent. Electrophysiological studies have demonstrated that repeated treatment with typical antipsychotic drugs such as haloperidol produces a decrease in the number of spontaneously active dopamine cells in the substantia nigra pars compacta and the ventral tegmental area. This is in contrast to the atypical antipsychotic drug clozapine, which only reduces the number of spontaneously firing dopamine neurons in the ventral tegmental area Bunney, 1983, 1985; White and Wang, 1983a,b; Grace and Bunney, 1986) . Therefore, the therapeutic efficacy of antipsychotic drugs is hypothesized to be due to the depolarization inactivation of the A10 mesolimbic dopamine system whereas the side-effect liability of chronic treatment with typical neuroleptics such as haloperidol is the result of a persistent depression of neuronal firing in the A9 nigrostriatal system. Subsequent studies have attempted to relate these electrophysiological results to functional neurochemical measures of extracellular dopamine concentrations in forebrain dopamine terminal regions such as the caudate-putamen, nucleus accumbens, and prefrontal cortex. Extracellular dopamine concentrations measured in vivo by microdialysis or voltammetry in the caudate-putamen following chronic haloperidol administration are either decreased Lane and Blaha, 1987; Hernandez and Hoebel, 1989; Ichikawa and Meltzer, 1990a ,b, 1991 See, 1991; Yamadaet al., 1991) , increased (Zhang et al., 1989), or unchanged (See, I99 1; See et al., 1992; Weidemann et al., 1992) . Of the fewer studies that have examined brain nuclei other than the caudate following chronic haloperidol, basal extracellular dopamine was either decreased or unaffected in the nucleus accumbens (DeBelleroche and Neal, 1982; Blaha and Lane, 1987; Lane and Blaha, 1987; Meltzer, 1990a,b, 199 I, 1992; See et al., 1992) and prefrontal cortex (Hernandez and Hoebel, 1989; Chen et al., 1992) . Similar studies of chronic clozapine administration have also yielded mixed findings. Although most investigators report no changes in caudate dopamine content after 2 1 d of chronic treatment with clozapine Meltzer, 1990a, 1991; Chen et al., 1991; Chai and Meltzer, 1992) dopamine concentrations in the nucleus accumbens and medial prefrontal cortex are either diminished Meltzer, 1990a, 1991; Chen et al., 1991) or unchanged (Chen et al., 1992) .
Since all antipsychotic drugs are dopamine antagonists to varying degrees, previous studies have focused on forebrain dopamine systems. There is increasing evidence, however, of an interaction between dopamine and the excitatory amino acid neurotransmitter glutamate. In particular, there is a substantial amount of anatomical and neurochemical evidence that dopamine can modulate corticostriatal glutamate efflux via the D-2 receptor (Garau et al., 1978; Schwartz et al., 1978; Mitchell and Doggett, 1980; Rowlands and Roberts, 1980; Theodorou et al., 198 1; Nieoullon et al., 1982; . Filloux et al., 1988; Kerkerian and Nieoullon, 1988; Maura et al., 1988 Maura et al., , 1989 Yamamoto and Davy, 1992) . Furthermore, others have reported a dysfunction of the glutamatergic system in schizophrenia (Kim et al., 1980 (Kim et al., , 1983 Nishikawa et al., 1983; Carlsson and Carlsson, 1990; Sherman et al., 199 la,b) . More recent studies have shown that acute administration of antipsychotic drugs selectively increases extracellular concentrations ofglutamate in the prefrontal cortex (Pehek et al., 1992; Daly and Moghaddam, 1993) . Therefore, the putative glutamatergic effects of chronic antipsychotic treatment may be an important component of the pharmacological profile of these drugs and may be dependent, in part, upon their antidopaminergic activity.
As noted above, in vivo pharmacological and neurochemical studies have focused on spontaneous or basal concentrations of dopamine in the caudate-putamen and/or nucleus accumbens, with much less attention directed to the prefrontal cortex. Collectively, these studies have yielded varied results. However, in light of the aforementioned ability of antipsychotic drugs to produce depolarization inactivation of midbrain dopamine neurons that project to forebrain terminal regions, it is possible that stimulated or local depolarization-induced release of dopamine and glutamate within nerve terminal areas may more consistently differentiate the possible brain region selective effects of chronic antipsychotic drug treatment. No singular in vivo study to date has systematically compared and contrasted the effects of chronic treatment of haloperidol and clozapine on basal and depolarization-induced dopamine and glutamate efflux in striatal and cortical brain regions.
Therefore, the purpose of this study was to examine in vivo whether chronic treatment with the atypical antipsychotic drug clozapine, compared to haloperidol, differentially affects basal and/or depolarization-induced dopamine and glutamate efflux measured by microdialysis in the caudate, nucleus accumbens, and prefrontal cortex of the awake-behaving rat.
Materials and Methods
Animals. Male Sprague-Dawley rats weighing between 190 and 220 gm were purchased from Zivic Miller Laboratory (Alison Park, PA) and used in all experiments. Animals were housed two per cage in a temperature controlled room (23°C) with a 12 hr/12 hr light/dark cycle. Food and water were available ad libitum.
Drug administration. Haloperidol(0.5 mg/kg), clozapine (20 mgkg), or 0.1 M tartaric acid vehicle (1 ml/kg) was administered intraperitoneally for 2 1 consecutive days. These doses and the regimen were based on previous studies comparing the differential in vivo electrophysiological and receptor binding characteristic of these drugs (Chiodo and Bunney, 1983; White and Wang, 1983; Stockmeier et al., 1993) . All drug solutions were prepared daily and adjusted to pH 5.7-6.0 with NaOH. Rats were weighed every other day and injected with the drugs between 0800 and 1 100. After 2 1 d of treatment, all rats weighed between 320 and 360 gm.
Surgery. Three days prior to the termination of the 21 d chronic treatment, rats were anesthetized with a combination of chloral hydrate (150 mg/kg, i.p.) and ketamine (50 mg/kg, i.p.). The skull was exposed and a 1 mm hole was drilled through the bone above the intended probe implantation site. A 21 gauge stainless steel guide cannula was then stereotaxically placed into the hole and onto the surface of the cortex overlying either the anterolateral striatum (1.2 mm anterior to bregma and 3.2 mm lateral to the midline suture), nucleus accumbens (+2.0 mm AP, f 1.6 mm LAT) or medial prefrontal cortex (+3.2 mm AP, 1-0.7 mm LAT) (Paxinos and Watson, 1982) . The guide cannula with a wire obturator was fixed to the skull with cranioplastic cement and three set screws. The vertical placement of the microdialysis probe at the tip of the membrane was 5.0 mm (caudate), 9.0 mm (nucleus accumbens), or 5.0 mm (medial prefrontal cortex) below the cortical surface (Paxinos and Watson, 1982) . At the time ofthe dialysis experiments and 3 d after surgery, all animals returned to their preoperative body weights.
Microdialysis probes. A concentric-shaped dialysis probe was constructed as previously described (Yamamoto and Pehek, 1990; Yamamoto and Davy, 1992) . The exposed portion of the membrane (SpectraPor/cellulose, 6000 MW cutoff) was 4.0 mm (caudate), 1.5 mm (nucleus accumbens), or 4.5 mm (medial prefrontal cortex). The dead volume of each probe was determined before each experiment to coordinate precisely the onset and termination of the 80 mM K+ infusion with the sample collection. The relative recoveries of the probes for dopamine at 23°C were lo%, 12%, and 16% for those probes placed in nucleus accumbens, caudate, and medial prefrontal cortex, respectively. Throughout these studies, variability in relative recoveries between probes of a specified membrane length (e.g., 4.5 mm) varied by less than 10%. Due to this consistency between probes designated for a specified brain region, all data are expressed in absolute concentrations and were not corrected for relative recovery.
Microdialysis perfusion. Perfusion flow was controlled by a multisyringe pump (Harvard Instruments, South Natick, MA) at 2.0 &min. A low dead volume liquid switch (Valco Instrument Co., Houston, TX) was positioned in line between the perfusion pump and a liquid swivel (Instech, Plymouth Meeting, PA). A Teflon tether was used to connect the swivel to the animal and served as a protective covering for the infusion tubing. The low-dead-volume liquid switch permitted the discrete transition to a perfusion medium containing 80 mM K+ without an interruption in flow rate and no disturbance to the animal. The KrebsRinger medium contained 122 mM NaCI, 3.0 mM KCl, 1.2 mM MgSO,, 0.4 mM KH,PO,, and 1.2 mM CaCL, pH 7.40. When a high K + buffer (80 mM) was used, an equivalent concentration of NaCl was withheld from the medium to maintain equal molarity.
Dialysis probes were inserted on the day of the dialysis experiment. All dialysis studies were conducted 24 hr after the last drug administration. Perfusion was initiated 3 hr prior to the collection of baseline samples. Dialysate samples were then collected every 30 min until a 1.5 hr stable baseline was obtained. The perfusion medium was then switched to the Krebs-Ringer medium containing 80 mM K' for 30 min and subsequently switched back to the normal medium for 1.5 hr.
At the end of each experiment, all probe placements were verified from frozen 40-@m-thick coronal sections.
Biochemical measurements. Dialysate samples were divided and assayed separately for dopamine or glutamate by HPLC with electrochemical detection according to our previously published methods (Donzanti and Yamamoto, 1988a,b) . Separation ofdopamine from metabolites was achieved with a 3 Frn Cl8 column (100 mm x 2.0 mm) (Phenomenex) and a mobile phase consisting of 32 mM citric acid, 54.3 mM sodium acetate, 0.074 mM Na,EDTA, 0.215 mM octyl sodium sulfate, and 3.0% methanol (pH 4.2). Flow rate was 0.40 ml/min. Detection was with a Princeton Applied Research Instrument model 400 Electrochemical Detector and a glassy carbon electrode maintained at a potential of 0.6 V.
A 20 ~1 aliquot of each dialysate sample was assayed for amino acids by precolumn derivatization with o-phthaldialdehyde.
The derivatization reagent was prepared by dissolving 27 mg of o-phthaldialdehyde in 1 ml of 100% methanol, 9 ml of 0.1 M sodium tetraborate (pH 9.4) and 10 ~1 of /3-mercaptoethanol. This stock solution was then diluted 1:3 with the 0.1 M sodium tetraborate. A 10 ~1 aliquot of the reagent solution was then added to the 20 ~1 dialysate sample. Derivatization was allowed to uroceed for 2.0 min before iniection onto the HPLC column. Glutamate was separated from other amino acids on a 3 pm Cl8 reversed-phase column (100 x 4.2 mm) (Phenomenex) and eluted with a 0.1 M sodium phosphate buffer (pH 6.4) containing 25% methanol and 50 mg/liter ofNazEDTA. Detection was at a glassy carbon electrode maintained at +0.7 V by an LC4B amperometric detector (Bioanalytical Systems, Inc.). Flow rate was 1.0 ml/min. Data analysis. The data were expressed in absolute concentrations (absolute recoveries) as pg or t&20 ~1 and analyzed by a multifactor analysis of variance with repeated measures followed by post hoc Scheffe tests for multiple comparisons. Only data from animals with accurate probe placements as determined by postmortem histological analysis were included in the data analysis.
Results
Basal concentrations of dopamine and glutamate in the caudate, nucleus accumbens, and medial prefrontal cortex after chronic (Fig. 3) . No other changes in basal dopamine levels were found in the caudate or nucleus accumbens after haloperidol or clozapine treatment. Basal extracellular concentrations of glutamate were significantly increased by haloperidol in both the caudate (Fig. 1 ) and nucleus accumbens (Fig. 2) ; however, the magnitude of increase in caudate (500%) was much greater than in the accumbens (75%) (p ~0.05). No changes in glutamate concentrations were noted in the medial prefrontal cortex (Fig. 3) .
To investigate whether a single injection of haloperidol produces increases in basal caudate glutamate concentrations, a separate group of rats were pretreated with either one injection of haloperidol (0.5 mg/kg, i.p.) or tartaric acid vehicle 24 hr prior to the dialysis perfusion. Basal concentrations ofglutamate were not different between controls (3.84 & 0.41 ng/20 ~1) and haloperidol-pretreated animals (3.62 & 0.38 r&20 ~1). K+ stimulation increased glutamate efflux equally in both groups (11.6 f 1.6 and 10.4 ? 1.7 ng/20 ~1 in the vehicle-and haloperidoltreated animals, respectively). Vertical bars are the mean k SEM of five to seven rats/group during a 1.5 hr baseline period. *, Significantly different (p < 0.05) from vehicle and haloperidol groups.
Perfusion for 30 min with 80 mM K+ increased extracellular concentrations of dopamine and glutamate in all three brain regions but the relative magnitude of increase differed for the two compounds. This was also dependent on the brain region examined. K+-stimulated dopamine efllux increased basal concentrations by 28-fold in caudate and 23-fold in nucleus accumbens. In contrast, extracellular dopamine concentrations in the medial prefrontal cortex increased by only 7.4-fold. The relative magnitude of stimulated glutamate efflux was significantly less than dopamine (p < 0.05) but the relative increase in glutamate was similar across brain regions. This varied from 3-fold for caudate to 2-and 2.7-fold for nucleus accumbens and medial prefrontal cortex, respectively.
The effects of depolarization-induced dopamine release in the three brain areas following chronic treatment with either vehicle, haloperidol, or clozapine are illustrated in Figures 4-6 . Stimulated dopamine efflux in all three regions was reduced by haloperidol treatment. Dopamine release was decreased by 77% in caudate (Fig. 4 ) 53% in nucleus accumbens (Fig. 5) and 36% in medial prefrontal cortex (Fig. 6) dopamine efflux were observed within any of the brain regions examined following clozapine treatment.
In separate experiments, tetrodotoxin (TTX) (10 PM) in a calcium-free perfusion medium was used to examine the neuronal contribution to the overall glutamate concentrations of the dialysate samples. Perfusion with a calcium-free medium containing TTX over a 2 hr period did not significantly decrease basal glutamate concentrations but did attenuate the K+-stimulated glutamate efflux by 68 + 7% in each of the three brain regions.
Stimulated glutamate efflux in the caudate, nucleus accumbens, and cortex was also selectively affected by chronic antipsychotic drug treatment (Figs. 7-9 ). There was an enhanced increase in extracellular glutamate in the nucleus accumbens following chronic clozapine treatment (Fig. 8) as well as in the caudate of haloperidol-treated animals (Fig. 7) . Although the absolute concentrations of glutamate during the 80 mM K+ perfusion in the caudate were significantly higher following chronic haloperidol compared to the other groups, the relative increase from basal values was not different between any of the drug conditions. Therefore, the only significant differences noted in 
Discussion
Chronic treatment with haloperidol or clozapine produced brain regiondependent effects on both basal and depolarization-induced glutamate and dopamine efflux measured by in vivo microdialysis. Chronic treatment with haloperidol selectively increased basal extracellular concentrations of glutamate in the caudate whereas treatment with the atypical antipsychotic drug clozapine increased basal extracellular dopamine concentrations only in the medial prefrontal cortex. In contrast to basal levels, depolarization-induced dopamine efflux was blunted in all three brain regions examined following chronic haloperidol treatment whereas stimulated glutamate efflux was enhanced in the nucleus accumbens after clozapine.
These data are the first evidence of elevated basal extracellular glutamate concentrations in the caudate and nucleus accumbens following chronic haloperidol administration. These results are different from those of Bardgett et al. (1993) , who demonstrated that acute but not chronic haloperidol administration resulted in higher tissue content levels of glutamate. in contrast to the present study, they reported that both acute and chronic clozapine administration decreased glutamate content in striatum. These differences could be accounted for by the fact that tissue content measures of glutamate reflect both intracellular and extracellular pools whereas dialysis perfusates reflect contents of the extracellular synaptic space.
The increase in extracellular glutamate in caudate after chronic haloperidol administration is consistent with a previous report by Moghhadam and Bunney (1993) . This effect could be due to a disinhibition of corticostriatal glutamatergic transmission via antagonism of the D-2 receptor produced by the accumulation of haloperidol in the brain. Along these lines, it has been shown that there are D-2 receptors located on corticostriatal nerve terminals (Garau et al., 1978; Schwartz et al., 1978; Theodorou et al., 1981; Filloux et al., 1989) and that dopamine and D-2 agonists inhibit stimulated glutamate efflux in the striaturn (Mitchell and Doggett, 1980; Rowlands and Roberts, 1980; Nieoullon et al., 1982; Kerkerian and Nieoullon, 1988; Maura et al., 1988 Maura et al., , 1989 Yamamoto and Davy, 1992) . Furthermore, chronic treatment with the D-2 antagonist (-)sulpiride increases glutamate in cerebrospinal fluid of rats (Kim et al., 1983) . In the present study, the fivefold increase in caudate glutamate is particularly striking in light of the lesser increase in the nucleus accumbens, the lack of effect in cortex, and the absence of any changes following chronic clozapine administration. The elevated concentrations of glutamate in caudate is not due to a persistent effect after the last injection of haloperidol since a single acute administration of haloperidol 24 hr before the dialysis experiment did not increase basal or augment stimulated glutamate efflux. However, a cumulative effect due to pharmacokinetic mechanisms following 2 1 d ofhaloperidol exposure must be taken into consideration. Our results are consistent with the interpretation of findings reported by Meshul and Casey (1989) who demonstrated a reversible increase in the number of perforated synapses within the dorsolateral caudate 24 hr following chronic haloperidol but not clozapine treatment. The perforated synapse has been hypothesized to be an indicator of increased neuronal activity (Meshul et al., 1989) . It also has been speculated that the haloperidol-induced increases in these synapses are due to activation of the excitatory corticostriatal pathway (Meshul and Casey, 1989; Meshul et al., 1992a,b) . Support for this interpretation is the ability of the NMDA antagonist MK 801 to reverse the haloperidol-induced increase in perforated synapses (Meshul et al., 1990) . It can be posited that the markedly elevated glutamate concentrations in the caudate may be related to the extrapyramidal side effects associated with chronic haloperidol treatment. The present results further highlight and support the hy- pothesis that tardive dyskinesia may be due to a glutamateinduced excitotoxic lesion ofthe striatal efferent motor pathways (Gunne and Andren, 1993 ). An analogous mechanism in the nucleus accumbens cannot easily explain the modest but significant increase in basal glutamate concentrations in this region following chronic haloperidol administration. Although there is no reported evidence of a specific D-2-mediated inhibition of corticoaccumbal glutamate release, the nucleus accumbens does receive excitatory inputs from the cortex (Christie et al., 1987; Groenewegen et al., 1987) that use glutamate and aspartate as transmitters (Fonnum, 1984; Perschak and Cuenod, 1990) . Along similar lines, there is a reported interaction between excitatory amino acids and dopamine efflux in the nucleus accumbens (Youngren et al., 1993) . Although the mechanism(s) for the enhancement of stimulated glutamate efflux in the nucleus accumbens following chronic clozapine treatment cannot be discerned from the present data, this effect could be due to the ability of clozapine to antagonize the S-HTz receptor . There are reports of a serotonergic modulation of dopamine efflux in the nucleus accumbens (Devaud and Hollingsworth, 199 1; Devaud et al., 1992) but there is no direct evidence to our knowledge that 5-HT can alter glutamate release in this region. It has been demonstrated in the cerebellum that 5-HT via the 5-HT, receptor can inhibit stimulated glutamate release, which in turn can be reversed by ketanserin (Maura et al., 1988) . Whether a similar mechanism is operative in the nucleus accumbens is not known. Although speculative, it is possible that the 5-HT, antagonist properties of clozapine may disinhibit stimulated glutamate release in the nucleus accumbens. This would be in contrast to the effects of haloperidol on the enhanced basal glutamate efflux in this area, which may be under control by the D-2 receptor. No definitive explanations regarding a serotonergic or dopaminergic involvement in the regional differences in basal and stimulated glutamate efflux can be offered at the present time.
The origin (neuronal vs metabolic) of basal extracellular glutamate concentrations in vehicle-treated rats probably is the metabolic pools, as evidenced by the lack of any change produced by the perfusion of TTX in a calcium-free perfusion medium. However, a majority of the K+-stimulated glutamate efflux appears to be calcium-and impulse-dependent as shown by a significantly attenuated response to K+ stimulation during the TTX/calcium-free perfusion. It still remains to be determined whether the increases in basal glutamate concentrations in caudate and the nucleus accumbens produced by chronic haloperidol treatment are from neuronal pools. Regardless of the origin, it is possible that these increases (75-500%) in extracellular glutamate concentrations can have receptor-mediated effects on striatal neurons. Furthermore, the enhancement of either basal or stimulated glutamate efflux by neuroleptic drugs in limbic regions such as the nucleus accumbens may have therapeutic implications. Several studies have demonstrated decreased glutamate release (Sherman et al., 199 1 b) and low CSF glutamate levels in the brains of schizophrenics (Kim et al., 1980) . These data are consistent with the theory that schizophrenia is a glutamatergic deficiency disorder (Carlsson and Carlsson, 1990; Sherman et al., 199 1 a) . Regardless of the role glutamate plays in schizophrenia, the present results provide evidence that elevated basal and/or enhanced depolarizationinduced increases in extracellular glutamate concentrations in extrapyramidal and limbic nuclei are components of the pharmacological profile of both typical and atypical antipsychotic drugs.
The present results of unaltered basal dopamine concentrations in caudate and nucleus accumbens following chronic treatment with haloperidol agree with some (DeBelleroche and Neal, 1982; Hernandez and Hoebel, 1989; See et al., 1991 See et al., , 1992 Weidemann and Wightman, 1992) but not other previous findings Lane and Blaha, 1987; Zhang et al., 1989; Meltzer, 1990, 199 1, 1992) . Electrophysiological studies predict that impulse-mediated dopamine release should be decreased. This is based on the observations that a depolarization inactivation of approximately 80% of the spontaneously active dopamine cells recorded within the A9 or Al0 regions is produced following chronic haloperidol or clozapine, respectively (Chiodo and Bunney, 1983; White and Wang, 1983a) . However, Robinson and Whishaw (1988) have shown that significant decreases in basal dopamine efflux as measured by microdialysis are not apparent until at least an 80% depletion of dopamine tissue content is produced. It is possible that a >90% elimination or inactivation of dopamine neurons is required to reveal marginally significant decreases in the extracellular dopamine concentrations as measured by microdialysis within terminal regions. Furthermore, it has been demonstrated that release from terminals produced by acute or chronic antipsychotic treatment may be dissociated from changes in dopamine neuron firing (Westerink and deVries, 1989; Grace, 199 1) . Thus, it is not surprising that results vary with regard to the effects ofchronic antipsychotic treatment on basal dopamine efflux in forebrain dopamine regions.
The underlying mechanism for the attenuation of stimulated dopamine release in the medial prefrontal cortex by chronic haloperidol is not known. These results are inconsistent with the findings that following chronic haloperidol administration, tolerance does not develop to the increases in dopamine synthesis and metabolism observed after a haloperidol challenge (Bannon et al., 1982) . However, the development of tolerance is dependent on the dose and duration of haloperidol administration (Scatton, 1977) . The present results suggest that haloperidol produces a decrease in dopaminergic function in the cortex. Since a hypofunction of dopaminergic input to the prefrontal cortex may be associated with the negative aspects of schizophrenia (e.g., anhedonia, social withdrawal; Mackay, 1990) this effect of haloperidol may contribute to its lack of efficacy in alleviating these symptoms.
The elevated basal concentrations of dopamine in the cortex after chronic clozapine treatment differs from the lack of change reported by Chen et al. (1992) . The methodology was very similar to the present study with the exception that they used a high CaCl, concentration in the perfusion medium (3.37 mrvr). The concentration used in the present study (1.2 mM) is within the physiological range of striatal extracellular fluid (Moghaddam and Bunney, 1989) . It is possible that mesocortical dopamine neurons are particularly sensitive to high Ca'+ concentrations and could have masked subtle differences in basal dopamine efflux. This explanation is supported by the well-established finding that mesocortical dopamine neurons have a higher tumover rate and a higher rate of impulse-mediated and thus Ca*+ -dependent activity (Bannon et al., 1981; Bannon and Roth, 1983) . Nevertheless, the selectively elevated dopamine concentrations in the cortex by chronic clozapine is similar to previous findings following acute administration (Moghaddam and Bunney, 1990 ) and may be partially responsible for the efficacy of this drug in treating the negative symptoms of schizophrenia (Meltzer, 1989) . One approach that can niaximize the probability of detecting region-dependent differences in impulse-mediated dopamine efflux as a function of antipsychotic drug treatment is to examine depolarization-induced dopamine release. As Figures 4-6 illustrate, chronic haloperidol significantly attenuated depolarization-induced dopamine release in all three brain regions whereas clozapine was without effect. These release data are consistent with previous electrophysiological studies and support the hypothesis that chronic haloperidol reduces depolarization-dependent dopaminergic activity Bunney, 1983, 1985; White and Wang, 1983a,b; Grace and Bunney, 1986) . In addition, the lack of any changes in basal or depolarization-induced dopamine efflux in any of the subcortical regions examined following chronic clozapine further highlight the nondopaminergic and perhaps glutamatergic (Fig. 8) or serotonergic activity of this drug.
local depolarization-induced dopamine as well as glutamate efIn conclusion. this studv demonstrates that both basal and flux in dopamine terminal fields are altered in a region-dependent manner by chronic antipsychotic drug treatment. This paradigm also appears to differentiate the neurochemical effects of chronic halopetidol and clozapine administration. The attenuation of stimulated dopamine release and the markedly elevated basal levels of glutamate in caudate may contribute to the side-effect liability of haloperidol.
In contrast, the enhancement of stimulated glutamate release by clozapine and the moderately elevated basal concentrations of glutamate after haloperidol in the nucleus accumbens may be partly responsible for the antipsychotic effects of these drugs. 
